Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.
Also called NCT01320202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 305 participants
- Registry
-
NCT01320202
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01320202. Randomized; single masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-04-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Acronym
- CRUISE 1
- Condition
- Renal Failure Chronic Requiring Hemodialysis
- Intervention (Drug)
- Soluble Ferric Pyrophosphate (SFP)
- Intervention (Device)
- Standard dialysate
- Lead sponsor
- Rockwell Medical Technologies, Inc.
Record details
- Record id
cardio:ct-nct01320202- Content hash
12728f9027cc83d620ab3f0e4b6b512dbb45e8dbfda5497df50f4750ed9a2148